Dr. Juan Pocholo B. Cancio, DDS in Los Angeles, California

Info
Map & Directions
  • No Records Found

    Sorry, no records were found. Please adjust your search criteria and try again.

    Google Map Not Loaded

    Sorry, unable to load Google Maps API.

  • Centro Medico and Dental Familiar

  • Dental Center San Miguel

  • Vernon-Central Caring Dentistry

  • Elizondo Laura K DDS

  • Historic Core Dental Care

    Verified

  • Saroj Dental Care

  • Aurora Sheboygan Prices – HEPARIN (PORCINE) IN NACL 30000-0.9 UNIT/L-% IV SOLN is $142.68

    At Aurora Medical Center Sheboygan, we prioritize providing our patients with comprehensive financial information upfront. For Charge Code 10002800, regarding HEPARIN (PORCINE) IN NACL 30000-0.9 UNIT/L-% IV SOLN, which is classified under revenue code 250 and associated with CPT code J1644, the designated fee stands at $142.68. Our aim through the CompareMedCosts program is to furnish you with all the details you need to make informed healthcare decisions, offering clarity and transparency around the costs associated with your care.

  • |
    Latest Advances in Neurology in 2025: Treatments Changing Patient Care

    In 2025, neurology is shifting toward earlier, more personalized, and less invasive care that meaningfully improves daily life. Blood-based biomarkers and AI-enhanced imaging are speeding diagnosis and helping match patients to the right treatments, while disease‑modifying options are expanding—from anti‑amyloid therapies for Alzheimer’s and genetics‑guided approaches in ALS to next‑generation therapies for MS and new migraine preventives. Targeted neuromodulation and wearable monitoring are reducing symptoms and hospital visits in epilepsy and movement disorders, and stroke care is faster and more effective with streamlined thrombolysis, improved thrombectomy, and home‑based rehabilitation. For patients, caregivers, and information seekers, these advances translate into clearer choices, more care delivered at home, better function with fewer side effects, and greater access to clinical trials when standard options are limited.